Biomerica Launches New Website for Its Aware® Breast Exam Device

  • Simple at-home breast exam device provides results within minutes
  • Studies show increase in Breast Exam Sensitivity

IRVINE, Calif. , Oct. 29, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that in conjunction with Breast Cancer Awareness month, which takes place each October, it has launched its new website for the Aware® at-home breast self-exam pad. Breast cancer is the most commonly-diagnosed cancer in women.   In 2021, an estimated 281,550 new cases of invasive breast cancer will be diagnosed and approximately 43,600 women will die from breast cancer in US.    One in eight women will develop invasive breast cancer in their lifetime.

The Aware® Breast exam pad is an FDA-cleared device. The product increases sensitivity in breast self-exams, making a self-exam easy and convenient.

Zack Irani, CEO of Biomerica, commented, “Early detection is one of the best ways to mitigate the most devastating effects of breast cancer. Our Aware® Breast Self-Exam Product allows patients to conduct a self-exam quickly and it enhances the sensitivity of the exam. We are pleased to launch the Aware® website to provide support and information to the users of our self-exam product, which can play an important role in the initial detection of abnormalities that may indicate the presence of disease.”

For further information about the Aware® Breast Self-Exam Product, please visit the Aware website at

About Biomerica (NASDAQ: BMRA)

Biomerica, Inc. ( is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point of care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica’s primary focus is on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking, such as statements relating to the efficacy of the Company’s EZ Detect and other tests, FDA clearance of the Company’s products, the rapidity of testing results, negotiations with international distribution partners, uniqueness of the Company’s products, enhanced sensitivity, test result accuracy of products, pricing of the Company’s test kits, demand for domestic or international orders, potential revenues from the sale of current or future products, availability of the Company’s test kits, and patent protection on any of the Company’s products or technologies. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, including, without limitation: results of studies testing the efficacy of the Company’s tests, InFoods tests and other products; regulatory approvals necessary prior to commercialization of the Company’s products; availability of the Company’s test kits and other products; capacity, resource and other constraints on our suppliers; dependence on our third party manufacturers; dependence on international shipping carriers; governmental import/export regulations; demand for our various tests and other products; competition from other similar products and from competitors that have significantly more financial and other resources available to them; governmental virus control regulations that make it difficult or impossible for the company to maintain current operations; the Company’s ability to comply with current and future regulations in the countries where our products are made and sold and the Company’s ability to obtain patent protection on any aspects of its rapid test technologies. Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. Additionally, potential risks and uncertainties include, among others, fluctuations in the Company's operating results due to its business model and expansion plans, downturns in international and or national economies, the Company's ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company's dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.

Corporate Contact:

John Nesbett /Jennifer Belodeau
IMS Investor Relations

Source: Biomerica, Inc.